Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients

被引:262
|
作者
Tisdale, James E. [1 ,2 ]
Jaynes, Heather A. [1 ]
Kingery, Joanna R. [3 ]
Mourad, Noha A. [1 ]
Trujillo, Tate N. [3 ]
Overholser, Brian R. [1 ,2 ]
Kovacs, Richard J. [2 ,4 ]
机构
[1] Purdue Univ, Coll Pharm, Dept Pharm Practice, Indianapolis, IN 46202 USA
[2] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA
[3] Indiana Univ, Hlth Methodist Hosp, Dept Pharm, Indianapolis, IN 46204 USA
[4] Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA
来源
基金
美国国家卫生研究院;
关键词
electrocardiography; predictors; QT interval; risk factors; torsades de pointes; TORSADE-DE-POINTES; LONG-QT; PROLONGING DRUGS; QUINIDINE; CARE; PREVALENCE;
D O I
10.1161/CIRCOUTCOMES.113.000152
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Identifying hospitalized patients at risk for QT interval prolongation could lead to interventions to reduce the risk of torsades de pointes. Our objective was to develop and validate a risk score for QT prolongation in hospitalized patients. Methods and Results In this study, in a single tertiary care institution, consecutive patients (n=900) admitted to cardiac care units comprised the risk score development group. The score was then applied to 300 additional patients in a validation group. Corrected QT (QT(c)) interval prolongation (defined as QT(c)>500 ms or an increase of >60 ms from baseline) occurred in 274 (30.4%) and 90 (30.0%) patients in the development group and validation group, respectively. Independent predictors of QT(c) prolongation included the following: female (odds ratio, 1.5; 95% confidence interval, 1.1-2.0), diagnosis of myocardial infarction (2.4 [1.6-3.9]), septic shock (2.7 [1.5-4.8]), left ventricular dysfunction (2.7 [1.6-5.0]), administration of a QT-prolonging drug (2.8 [2.0-4.0]), 2 QT-prolonging drugs (2.6 [1.9-5.6]), or loop diuretic (1.4 [1.0-2.0]), age >68 years (1.3 [1.0-1.9]), serum K+ <3.5 mEq/L (2.1 [1.5-2.9]), and admitting QT(c) >450 ms (2.3; confidence interval [1.6-3.2]). Risk scores were developed by assigning points based on log odds ratios. Low-, moderate-, and high-risk ranges of 0 to 6, 7 to 10, and 11 to 21 points, respectively, best predicted QT(c) prolongation (C statistic=0.823). A high-risk score 11 was associated with sensitivity=0.74, specificity=0.77, positive predictive value=0.79, and negative predictive value=0.76. In the validation group, the incidences of QT(c) prolongation were 15% (low risk); 37% (moderate risk); and 73% (high risk). Conclusions A risk score using easily obtainable clinical variables predicts patients at highest risk for QT(c) interval prolongation and may be useful in guiding monitoring and treatment decisions.
引用
收藏
页码:479 / 487
页数:9
相关论文
共 50 条
  • [11] QT interval prolongation in hospitalized patients on cardiology wards: a prospective observational study
    Khan, Qasim
    Ismail, Mohammad
    Haider, Iqbal
    ul Haq, Inam
    Noor, Sidra
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (11) : 1511 - 1518
  • [12] Risk factors of QT interval prolongation in Japanese patients with schizophrenia
    Ozeki, Y.
    Aoki, T.
    Fujii, K.
    Kurimoto, N.
    Takahashi, J.
    Ishida, N.
    Narita, M.
    Yamada, N.
    Saitoh, O.
    Horie, M.
    Kunigi, H.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 149 - 149
  • [13] Development and Validation of a Clinical Risk Score to Predict the Critical Illness in Hospitalized Patients With COVID-19
    Katsouli, Anthi
    Gazi, Sadia
    Marfia, Paula
    Lee, Helen
    Qazi, Sameer
    Komorowski, Monica
    Bertino, Ann-Marie
    Joshi, Neeraj
    CIRCULATION, 2021, 144
  • [14] PROLONGATION OF THE QT INTERVAL IN PATIENTS WITH EPILEPSY
    RAINEY, JM
    CHAYASIRISOBHON, S
    EPILEPSIA, 1983, 24 (01) : 115 - 115
  • [15] MEASUREMENT OF THE QT INTERVAL AND THE RISK ASSOCIATED WITH QT(C) INTERVAL PROLONGATION - A REVIEW
    MOSS, AJ
    AMERICAN JOURNAL OF CARDIOLOGY, 1993, 72 (06): : B23 - B25
  • [16] Multifactorial QT Interval Prolongation: The Risk of Polypharmacy
    Digby, G.
    Perez Riera, A. R.
    Barros, R. B.
    de Sousa Belem, L.
    Fong, C.
    Methot, M.
    Femenia, F.
    Baranchuk, A.
    NEW HORIZONS IN CARDIOVASCULAR DISEASES, 2010, : 241 - 244
  • [17] The preclinical assessment of the risk for QT interval prolongation
    Champeroux, P
    Martel, E
    Vannier, C
    Blanc, V
    Leguennec, JY
    Fowler, J
    Richard, S
    THERAPIE, 2000, 55 (01): : 101 - 109
  • [18] Reconciling the risk of QT interval prolongation in antidepressants
    McKean, Alastair J.
    Sola, Christopher L.
    Galardy, Christine
    Kung, Simon
    Lineberry, Timothy W.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 (03) : 329 - 330
  • [19] MULTIFACTORIAL QT INTERVAL PROLONGATION: THE RISK OF POLYPHARMACY
    Digby, G. C.
    Riera, A. R.
    Barros, R. B.
    Belem, L. S.
    Fong, C.
    Methot, M.
    Femenia, F.
    Baranchuk, A. M.
    CANADIAN JOURNAL OF CARDIOLOGY, 2010, 26 : 132D - 132D
  • [20] Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19
    Liang, Wenhua
    Liang, Hengrui
    Ou, Limin
    Chen, Binfeng
    Chen, Ailan
    Li, Caichen
    Li, Yimin
    Guan, Weijie
    Sang, Ling
    Lu, Jiatao
    Xu, Yuanda
    Chen, Guoqiang
    Guo, Haiyan
    Guo, Jun
    Chen, Zisheng
    Zhao, Yi
    Li, Shiyue
    Zhang, Nuofu
    Zhong, Nanshan
    He, Jianxing
    JAMA INTERNAL MEDICINE, 2020, 180 (08) : 1081 - 1089